“DPP-4 inhibitors are proving to be more than just blood sugar controllers — they may reshape the way we approach diabetes care.”

A comprehensive review published in Angiotherapy Research on January 8, 2024 explores the role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in managing Type 2 Diabetes Mellitus (T2DM). The article, titled “A Review of Dipeptidyl Peptidase-4 (DPP-4) and its potential synthetic derivatives in the management of Diabetes Mellitus” is authored by Mohd. Javed Naim

The review explains how DPP-4 inhibitors work by blocking the enzyme responsible for breaking down incretin hormones such as GLP-1 and GIP. By doing so, they help the body produce more insulin, suppress excess glucagon, and lower glucose levels after meals. Clinical trials consistently demonstrate that DPP-4 inhibitors effectively reduce HbA1c levels, with results comparable to metformin or sulfonylureas.

“These qualities render them a compelling option for patients with type 2 diabetes mellitus who are overweight or susceptible to hypoglycemia episodes,” writes Naim. Unlike many traditional diabetes medications, DPP-4 inhibitors are weight-neutral and carry a lower risk of hypoglycemia, making them a safer choice for many patients.

However, the review cautions about potential risks, including pancreatitis, nasopharyngitis, and drug–drug interactions, stressing the need for long-term safety studies.